Skip to content
Citation only via Europe PMC

Gut Microbiota in Alzheimer's Disease and Healthy Aging: Mechanisms, Prevention Strategies and Healthcare Burden.

Çeli̇k MN, Mohammadzadeh M, Ahıskalı Öksüz M, Coşkun Us N, Ünlü Söğüt M.

Current nutrition reports · 2026

Abstract

<h4>Purpose of review</h4>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline associated with oxidative stress, neuroinflammation, tau neurofibrillary tangles, amyloid-beta plaque deposition, and metabolic dysfunction. Increasing evidence suggests that the gut microbiota plays an important role in AD pathogenesis through the microbiota-gut-brain axis. This review aims to provide a comprehensive overview of the role of the gut microbiota in AD and healthy aging, with a particular focus on microbiota-targeted preventive and therapeutic strategies and their potential to influence disease progression.<h4>Recent findings</h4>Recent studies have demonstrated that alterations in gut microbial composition are closely associated with AD. Patients with AD commonly exhibit a reduced abundance of short-chain fatty acid-producing bacteria and an increased prevalence of lipopolysaccharide-producing taxa, supporting a mechanistic link between microbial dysbiosis, systemic inflammation, and neurodegeneration. Emerging evidence indicates that dietary patterns, prebiotics, probiotics, synbiotics, postbiotics, and microbiota-based therapies, including fecal microbiota transplantation (FMT), may beneficially modulate gut microbial composition and influence AD-related pathophysiological processes. In addition, lifestyle factors such as sleep quality and physical activity have been increasingly recognized for their interactions with the gut-brain axis and their potential to affect cognitive health. Current evidence highlights the gut microbiota as a promising therapeutic target in AD prevention and management. Microbiota-directed interventions, together with healthy dietary and lifestyle modifications, may help attenuate neuroinflammation, improve metabolic homeostasis, and delay cognitive decline. Furthermore, given the substantial global economic burden of AD, microbiota-focused preventive strategies may contribute not only to improving clinical outcomes but also to reducing long-term healthcare and societal costs. Future longitudinal and interventional studies are needed to establish causal relationships and determine the efficacy of microbiota-based therapies in AD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1007/s13668-026-00812-x
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
MN, �., M, M., M, A.�., N, C.U., &amp; M., �.S. (2026). Gut Microbiota in Alzheimer's Disease and Healthy Aging: Mechanisms, Prevention Strategies and Healthcare Burden. <em>Current nutrition reports</em>. https://doi.org/10.1007/s13668-026-00812-x
Vancouver
MN �, M M, M A�, N CU, M. �S. Gut Microbiota in Alzheimer's Disease and Healthy Aging: Mechanisms, Prevention Strategies and Healthcare Burden. Current nutrition reports. 2026. doi:10.1007/s13668-026-00812-x.
BibTeX
@article{elik2026GutMic, title = {Gut Microbiota in Alzheimer's Disease and Healthy Aging: Mechanisms, Prevention Strategies and Healthcare Burden.}, author = {Çeli̇k MN and Mohammadzadeh M and Ahıskalı Öksüz M and Coşkun Us N and Ünlü Söğüt M.}, journal = {Current nutrition reports}, year = {2026}, doi = {10.1007/s13668-026-00812-x}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings